Skip to main content

Table 2 Treatment combinations among patients with a subsequent line of therapy

From: EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

Subsequent line of therapyPatients who received 1 L EGFR-TKI and had subsequent therapy (N = 160),
n (%)
Patients who received 2 L+ EGFR-TKI and had subsequent therapy (N = 134),
n (%)
Chemotherapy alone25 (15.6)29 (21.6)
Immunotherapy alone22 (13.8)55 (41.0)
Targeted therapies  
 EGFR-TKI  
  Alone93 (58.1)23 (17.2)
  Plus chemotherapy3 (1.9)3 (2.2)
  Plus immunotherapy3 (1.9)2 (1.5)
  Plus other targeted therapies2 (1.3)2 (1.5)
  Plus chemotherapy, other targeted therapies1 (0.6)3 (2.2)
 Other targeted therapies  
  Alone4 (2.5)2 (1.5)
  Plus chemotherapy6 (3.8)14 (10.4)
 Clinical study druga1 (0.6)1 (0.7)
  1. 1 L first line, 2 L+ second or later line, EGFR epidermal growth factor receptor, EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor
  2. a Flatiron Health masks the names of clinical study drugs in the data due to the sensitive nature of patients in clinical trials